Guidance For Industry Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects
Contains Nonbinding Recommendations
TABLE OF CONTENTS
I. INTRODUCTION
II. OVERVIEW OF INVESTIGATOR RESPONSIBILITIES
III. CLARIFICATION OF CERTAIN INVESTIGATOR RESPONSIBILITIES
A. Supervision of the Conduct of a Clinical Investigation
1. What Is Appropriate Delegation of Study-Related Tasks?
2. What Is Adequate Training?
3. What Is Adequate Supervision of the Conduct of an Ongoing Clinical Trial?
4. What Are an Investigator’s Responsibilities for Oversight of Other Parties Involved in the Conduct of a Clinical Trial?
B. Protecting the Rights, Safety, and Welfare of Study Subjects
1. Reasonable Medical Care Necessitated by Participation in a Clinical Trial.
2. Reasonable Access to Medical Care.
3. Protocol Violations that Present Unreasonable Risks.
ATTACHMENT A: COPY OF FORM 1572.
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Additional copies are available from:
Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
(Tel) 301-827-4573
http://www.fda.gov/cder/guidance/index.htm or
Office of Communication, Training and Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
http://www.fda.gov/cber/guidelines.htm (Tel) 800-835-4709 or 301-827-1800 or
Office of Health and Industry Programs
Division of Small Manufacturers, International, and Consumer Assistance, HFZ-220
Center for Devices and Radiological Health
Food and Drug Administration
Tel: 1-800-638-2041
http://www.fda.gov/cdrh U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Procedural
October 2009
Clinical Research News
Upcoming Clinical Research Events
-
29 September 2023 – 02 October 2024
SCDM (Society of Clinical Data Management)
United States -
11 – 12 December 2023
Informa
Online -
08 – 11 February 2024
AMIA (American Medical Informatics Association)
United States -
10 – 11 April 2024
The Society for Clinical Research Sites (SCRS)
United States -
16 – 18 April 2024
Informa
United States -
17 – 19 April 2024
SCDM (Society of Clinical Data Management)
Poland -
21 – 23 May 2024
Informa
Belgium -
03 – 04 June 2024
The Society for Clinical Research Sites (SCRS)
United States -
16 – 17 July 2024
The Society for Clinical Research Sites (SCRS)
Australia -
27 September – 29 October 2024
The Society for Clinical Research Sites (SCRS)
United States
Aankomende klinische onderzoeken
-
Apellis Pharmaceuticals, Inc.WervingGeografische atrofieVerenigde Staten
-
Karamanoğlu Mehmetbey UniversityWervingHospitalisme bij kinderenKalkoen
-
University of Wisconsin, MadisonNog niet aan het wervenPilot-effectiviteitsproef van een ACT-zelfhulpwerkboek, specifiek op maat gemaakt voor gevangenissenDepressie | Angst stoornissen | Ongerustheid | Depressie, angst
-
Assiut UniversityNog niet aan het wervenTrombocytopenie bij chronische nierziekte
-
Michigan State UniversityArizona State UniversityNog niet aan het wervenHPV-infectie | Door vaccinatie te voorkomen ziektenVerenigde Staten
-
Bitlis Eren UniversityNog niet aan het wervenErectiestoornissenKalkoen
-
Yisheng Biopharma (Singapore) Pte. Ltd.Nog niet aan het werven
-
University of PittsburghUnited States Agency for International Development (USAID); Oak Crest Institute...Nog niet aan het wervenVeiligheid | AanvaardbaarheidVerenigde Staten, Zuid-Afrika, Zimbabwe
-
Nationwide Children's HospitalRigel PharmaceuticalsNog niet aan het wervenAstrocytoom | Hooggradig glioom | Oligodendroglioom | Diffuus intrinsiek ponsglioom | Diffuus middellijnglioom, H3 K27M-mutant | WHO graad III glioom | Metastatische hersentumor | Spinale tumor | Astrocytoom, graad III | Astrocytoom, graad IV | IDH1-mutatie | WHO Graad IV Glioom | Thalamus-tumor | IDH1 R132 | IDH1 R132C en andere voorwaardenVerenigde Staten, Australië, Verenigd Koninkrijk, Canada, Duitsland, Nederland
-
Centre hospitalier de l'Université de Montréal...Optina Diagnostics Inc.WervingBijdrage van de kinematische theorie in de vroege differentiële diagnose van de ziekte van ParkinsonGezond | Ziekte van Parkinson | Parkinson-syndroomCanada
-
Renmin Hospital of Wuhan UniversityWerving
-
National Institute for Mother and Child Health...Marie Curie Emergency Children's Hospital, Bucharest; Victor Gomoiu Children's...WervingChronische granulomateuze ziekteRoemenië